Paxlovid looks good for permanent FDA approval

A US Food and Drug Administration (FDA) advisory committee has voted by 16 to one that data support the safety and effectiveness of Paxlovid (nirmatrelvir/ritonavir) for mild-to-moderate COVID-19 in adults at high risk for progression to severe illness.

The Antimicrobial Drugs Advisory Committee’s (AMDAC) vote will be considered by the FDA when making its decision regarding the potential permanent approval of Pfizer’s (NYSE: PFE) antiviral drug, which was granted emergency authorization in December 2021.

Decision due in May